EDITORIAL

Inversion Innovation
One of the biggest corporate stories of the year was the $160 billion aborted Pfizer-Allergan mega-merger. Initiated partially based on potential benefits of a tax inversion strategy, the U.S. Treasury changed the law to prohibit the inversion and so Pfizer paid a penalty of $400 million to terminate the deal.
Although commentary on the merits of rewriting the U.S. tax code to discourage inversions is beyond the scope of this Journal, we can think of at least one creative tax strategy opportunity that could jump-start innovation.
It is well know that the scale of the available capital stashed by American corporations overseas is staggering-estimates put the total at $2.1 trillion.* Indeed many (bio)pharmaceuctical companies that are household names to PDA members (Merck, Pfizer, Johnson & Johnson) alone account for tens of billions of dollars in ex-U.S. banks.
Traditionally, all these companies spend more on sales and marketing than on research and development despite the current tax breaks given for R&D spending. There are many, many critical diseases and emerging threats that would greatly benefit from long-range and proactive R&D. For example, as the previous editorial showed, rare diseases continue to exist for lack of available therapies. In terms of emerging threats, Zika is the current threat of the year, having emerged after Ebola, MERS, and SARS. And despite its urgency, federal Zika funding is struggling to make it out of Congress as we write this editorial.
So here is a radical notion-what if the substantial funds held overseas to minimize significant re-patriation taxes were permitted to come back into the U.S. tax-free, with the provision that these funds were all invested in R&D, either internally within a company or jointly with the public sector? Could this lead to a new paradigm of public-private partnership that would be a win-win all around? Greater R&D will lead to greater availability of lifesaving interventions and preparedness for unexpected threats. It would also result in recouping of any lost revenues due to the repatriation tax breaks by taxes on the increased economic activity from new products. What better way to strengthen the innovation engine that has driven the success of pharma and biotech, and use stranded capital to boost U.S. research and developing spending? 
